Short answer
Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Board authorized repurchases of up to $5 million in common stock following Takeda’s $20 million development milestone payment.
Keros Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Board authorized repurchases of up to $5 million in common stock following Takeda’s $20 million development milestone payment
- Cash and equivalents totaled $257.6 million as of June 30, 2026
- Management expects liquidity to fund operating expenses and capital requirements into the second half of 2028
- Repurchase signals capital-return flexibility while preserving a multiyear operating runway
Item EX-99.1 · Exhibit EX-99.1
- $5 million share repurchase authorization following $20 million elritercept milestone payment from Takeda
- Repurchases may occur in open-market transactions or other lawful methods
- Authorization is discretionary, with no obligation to repurchase shares
- Capital allocation signals confidence while returning part of milestone proceeds to shareholders
- Program timing and size subject to stock price, market conditions and contractual constraints
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Keros Therapeutics, Inc. 8-K filings
Get the next KROS 8-K as it lands
Follow KROS for push alerts, or ask the research agent what this filing means.